Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On June 6, 2024, Soligenix, Inc. (SNGX) enacted a reverse stock split at a ratio of 1 post-split share for every 16 pre-split shares.</li><li>Our valuation has been adjusted accordingly.</li><li> The company recently completed a public offering for gross proceeds of approximately $4.75 million.</li></ul>

On June 6, 2024, Soligenix, Inc. (SNGX) enacted a reverse stock split at a ratio of 1 post-split share for every 16 pre-split shares.Our valuation has been adjusted accordingly. The company recently completed a public offering for gross proceeds of approximately $4.75 million.

SNGX: Valuation Change Based on Reverse Split 

<ul><li>On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company recently completed a public offering for gross proceeds of approximately $4.75 million.</li><li>This capital infusion is important as the company prepares to initiate a second Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of cutaneous T cell lymphoma (CTCL).</li></ul>

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update.The company recently completed a public offering for gross proceeds of approximately $4.75 million.This capital infusion is important as the company prepares to initiate a second Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of cutaneous T cell lymphoma (CTCL).

SNGX: Second Confirmatory Phase 3 Trial of HyBryte  in CTCL to Initiate Before End of 2024 

United States

Soligenix, Inc. develops therapeutics and vaccines.  The Company researches treatments for gastrointestinal Graft-versus-Host disease and cancer, and develops vaccines for military and civilian applications.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Soligenix (SNGX US)

SNGX: Valuation Change Based on Reverse Split

On June 6, 2024, Soligenix, Inc. (SNGX) enacted a reverse stock split at a ratio of 1 post-split share for every 16 pre-split shares. Our...

Zacks Small Cap Research

SNGX: Second Confirmatory Phase 3 Trial of HyBryte in CTCL to Initiate Before End of 2024

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update. The company...

Zacks Small Cap Research

SNGX: Second Confirmatory Phase 3 Trial of HyBryte in CTCL to Initiate Before End of 2024

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update. The company...

Zacks Small Cap Research

SNGX: Second Confirmatory Phase 3 Trial of HyBryte in CTCL to Initiate Before End of 2024

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update. The company...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)